| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $170.4M | +104.5% |
| R&D Expense | $228.3M | +9.5% |
| SG&A Expense | $82.9M | +8.1% |
| Operating Income | -$161.2M | +30.9% |
| Pre-tax Income | -$193.9M | +14.6% |
| Income Tax | $0 | — |
| Net Income | -$193.9M | +14.6% |
| EPS (Basic) | -$3.76 | +18.1% |
| EPS (Diluted) | -$3.76 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $34.5M | -40.1% |
| Short-term Investments | $195.6M | +10.4% |
| Accounts Receivable | $26.4M | +28.8% |
| Current Assets | $281.3M | +1.2% |
| Total Assets | $453.0M | -2.8% |
| Current Liabilities | $118.1M | +14.4% |
| Total Liabilities | $350.3M | +69.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$124.0M | +28.4% |
| Capital Expenditures | $2.4M | -0.9% |
| Investing Cash Flow | -$15.9M | -115.3% |
| Financing Cash Flow | $116.8M | +26.0% |
| Free Cash Flow | -$126.4M | +28.0% |
| +18.1% |
| Stockholders' Equity |
| $102.7M |
| -60.4% |